Novo Nordisk intends to use the SCALE Kids trial to expand the Saxenda (liraglutide) label for children six years or older with obesity
ECC5004 further strengthens our existing pipeline addressing both incretin and non-incretin pathways, including our GLP-1/glucagon dual agonist [AZD9550] and long-acting amylin analogue [AZD6234]. Preliminary results from a Phase I trial in the United States suggest ECC5004 has a different profile from most of the current drugs, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo
"I would participate, but I definitely wouldn't climax, or if I did, it took a lot of effort
NF1 is characterized by multiple benign neurofibromas, caf-au-lait spots, and an increased lifetime risk (approximately 813%) of developing MPNST (Evans et al., 2021)
A1C or Blood Glucose One important biomarker while on a GLP-1 drug is blood glucose, or your blood sugar levels